MedPath

Hospital Airway Resuscitation Trial

Not Applicable
Recruiting
Conditions
Cardiac Arrest
Respiratory Failure
Interventions
Procedure: A strategy of first choice supraglottic airway
Procedure: A strategy of first choice endotracheal intubation
Registration Number
NCT05520762
Lead Sponsor
Montefiore Medical Center
Brief Summary

The Hospital Airway Resuscitation Trial (HART) is a cluster-randomized, pragmatic trial of advanced airway management with a strategy of first choice supraglottic airway vs. first choice endotracheal intubation during in-hospital cardiac arrest.

Detailed Description

In-hospital cardiac arrest occurs in nearly 300,000 hospitalized patients in the United States each year and results in substantial morbidity and mortality. Nevertheless, the evidence base guiding the management of in-hospital cardiac arrest is quite limited and society guidelines generally extrapolate data from the out-of-hospital cardiac setting to inform in-hospital arrest care. As compared to out-of-hospital arrest, however, in-hospital arrest victims tend to have more medical comorbidities, have a witnessed arrest, and be attended to by professional first responders with advanced monitoring and treatment capabilities. Advanced airway management is a key element of cardiac arrest resuscitation. The American Heart Association makes broad recommendations regarding airway management during in-hospital cardiac, supporting endotracheal intubation (a complex procedure requiring placement of an endotracheal tube through the vocal cords) and supraglottic airway placement (a less complex advanced airway modality wherein the device is placed blindly in the supraglottic space). Data from the out-of-hospital cardiac arrest setting has found that a supraglottic airway strategy may be similar or superior to a more complex endotracheal intubation strategy. There is no randomized data to guide practice in the in-hospital setting. We intend to address this knowledge gap by performing the Hospital Airway Resuscitation Trial (HART)-a highly-innovative, pragmatic cluster-randomized trial leveraging the unified clinical and research infrastructure within the Montefiore HealthSystem (New York City) to conduct a first-of-its-kind in-hospital arrest trial in a highly diverse patient population. Specifically, a mixture of academic and community hospitals within the MontefioreHealth system will be randomized to either a strategy of first-choice endotracheal intubation or a strategy of first choice supraglottic airway, with crossovers occurring at regular intervals. Key outcomes for the trial will include return of spontaneous circulation, alive-and-ventilator-free days, and hospital survival.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
1060
Inclusion Criteria
  1. Adult aged >=18 years
  2. Admitted to the hospital for any condition
  3. Suffered in-hospital cardiac arrest (loss of pulse and ≥2 minutes of chest compressions)
  4. Need for assisted ventilation (defined by initiation of bag-mask-ventilation or other supported ventilation)
Exclusion Criteria
  1. Cardiac arrest in the Operating Room or other area not responded to by critical care/ED (Emergency Department) teams.
  2. Cardiac arrest in which an invasive airway (i.e. endotracheal tube, tracheostomy tube) is already in place
  3. Patients with Do Not Resuscitate or Do Not Intubate orders

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
First choice endotracheal intubation, Then First choice supraglottic airwayA strategy of first choice supraglottic airwayA strategy of 'first choice' endotracheal intubation during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
First choice endotracheal intubation, Then First choice supraglottic airwayA strategy of first choice endotracheal intubationA strategy of 'first choice' endotracheal intubation during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
First choice supraglottic airway device, Then First choice endotracheal intubationA strategy of first choice endotracheal intubationA strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
First choice supraglottic airway device, Then First choice endotracheal intubationA strategy of first choice supraglottic airwayA strategy of 'first choice' supraglottic airway during cardiac arrest. Clinicians can deviate to the airway management approach of their choice if deemed to be in the best interest of the patient. As part of a cluster-randomized design, hospitals (4 in the system) will be assigned to one arm for a month and then cross-over to the other arm.
Primary Outcome Measures
NameTimeMethod
Alive-and-ventilator free daysFrom cardiac arrest until 28-days after cardiac arrest

Days alive and free of mechanical ventilation.

Secondary Outcome Measures
NameTimeMethod
Return of spontaneous circulation (ROSC)Onset of cardiac arrest until either ROSC or death up to 24 hours

Rate of ROSC. ROSC defined as 20 minutes of continuous spontaneous circulation without chest compressions.

72-hour survivalFrom cardiac arrest until 72 hours after cardiac arrest

Survival to 72-hour after cardiac arrest

Survival to hospital dischargeCardiac arrest until 60 days after cardiac arrest

Survival to hospital discharge, truncated at 60 days

Prolonged pausesFrom start of chest compressions during cardiac arrest until ROSC or death up to 24-hours

Number of prolonged pauses (\>5 seconds) in chest compressions during active Cardiopulmonary Resuscitation (CPR)

Chest compression fractionFrom start of chest compressions during cardiac arrest until ROSC or death up to 24-hours

Percentage of total cardiac arrest time during which chest compressions are being performed

Rate of ventilator-associated pneumonia (VAP)Cardiac arrest until 7 days after cardiac arrest

Rate of VAP in the 7 days after cardiac arrest. VAP defined as new pneumonia while receiving mechanical ventilation after cardiac arrest. New pneumonia defined by 1) new pulmonary infiltrate on chest imaging 2) either new/worsening fever or leukocytosis 3) either change in sputum composition/frequency or worsening gas exchange or new/worsening cough or dyspnea

Modified Rankin ScaleTime of hospital discharge

Modified Rankin Scale (mRS) at time of hospital discharge

Time to epinephrineTime from initiation of chest compressions to first epinephrine for cardiac arrest with initial non-shockable rhythm

Time from initiation of chest compressions to first epinephrine for cardiac arrest with initial non-shockable rhythm

Time to advanced airwayTime from initiation of chest compressions to advanced airway placement

Time from initiation of chest compressions to advanced airway placement

Number of Overall Pauses in Chest CompressionAt time of cardiac arrest, less than one day

The number of overall pauses in chest compression, greater than 5 seconds in duration, will be summarized by arm using basic descriptive statistics. It is hypothesized that SGA placement will result in fewer chest compression pauses

Longest Overall Pause in Chest CompressionAt time of cardiac arrest, less than one day

The duration of the longest overall pause in chest compression will be determined. This interval will be summarized by arm using basic descriptive statistics. It is hypothesized that SGA placement will result in chest compression pauses of shorter durations.

Trial Locations

Locations (1)

Montefiore Medical Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath